332235
Alternative Names: SB 332235Latest Information Update: 13 Jun 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Interleukin 8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Psoriasis
Most Recent Events
- 01 Dec 2004 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 01 Dec 2004 Discontinued - Preclinical for Psoriasis in United Kingdom (PO)
- 12 Oct 2004 Data presented at the 228th American Chemical Society National Meeting (228th-ACS-2004) have been added to the pharmacokinetics and Respiratory Tract Disorders pharmacodynamics sections